FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS

Sponsor
Trace Neuroscience, Inc.
Study ID
NCT07674667
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • TRCN-1023 — DRUG
    TRCN-1023 administered as an intrathecal injection.
  • Placebo — OTHER
    Intrathecal injection of artificial cerebrospinal fluid (aCSF).

Study Details

The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS. TRCN-1023 is an investigational medicine given as a single injection into the fluid surrounding the spine (intrathecal injection). The trial will also assess how the body processes the drug and whether it shows early signs of benefit over 24 weeks.

Key Dates

Start date
Jul 31, 2026
Status verified
Jun 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: TRCN-1023
    Antisense oligonucleotide (ASO) administered by intrathecal injection
  • Placebo Comparator: Placebo
    Matching Placebo Comparator

Primary Outcome Measure

Frequency of Adverse Events [ Time Frame: 24 Weeks ]

Related Studies